Roivant offloads biotech stakes in $3B alliance with Japanese pharma

Share

Sumitomo Dainippon Pharma will pay Roivant Sciences $3B for its stake in five of its subsidiaries and take a more than 10% stake in the parent company. Sumitomo Dainippon also gains the option to acquire Roivant’s stake in six more subsidiaries with up to 25 pipeline projects.

 

Sumitomo Dainippon is looking to replace lost revenue from the looming U.S. patent expiration on its biggest seller, Latuda, which had sales of more than $1.7B in the 2018 fiscal year.

 

Read the full article at biopharmadive.com…

Share

Leave a Reply

Your email address will not be published. Required fields are marked *

More in News & Trends
Amgen buying Celgene’s Otezla in $13B deal

Amgen will buy the psoriasis and arthritis drug Otezla from Celgene for $13.4B in a rare instance of an approved...

Close